Fabry disease: Diagnosis and treatment

Kidney International, Supplement

Volumn 63, Issue 84, 2003, Pages

  Breunig, Frank ^a,b   Weidemann, Frank ^a   Beer, Meinrad ^a   Eggert, Andreas ^a   Krane, Vera ^a   Spindler, Matthias ^a   Sandstede, Jörn ^a   Strotmann, Jörg ^a   Wanner, Christoph ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Clinical trial; Fabry disease; Genetic disorders; Lysosomal storage disease

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; CARBAMAZEPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GABAPENTIN; PHENYTOIN; RECOMBINANT ALPHA GALACTOSIDASE; UNCLASSIFIED DRUG;

CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE COURSE; DRUG SYNTHESIS; ECHOCARDIOGRAPHY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FABRY DISEASE; FOLLOW UP; GENE THERAPY; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HETEROZYGOTE; HUMAN; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; LIPID STORAGE; LONG TERM CARE; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RECOMBINANT GENE; TREATMENT OUTCOME; ULTRASOUND; X CHROMOSOME LINKAGE; REVIEW;

FABRY DISEASE; HUMANS;

EID: 0037406311     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.63.s84.5.x     Document Type: Conference Paper

References (32)

1. FABRY J: Ein Beitrag zur Kenntnis der purpura haemorrhagica nodularis (Purpura haemorrhagica nodularis hebrae). Arch Derm Syph 43:187-200, 1898
2. ANDERSON W: A case of angiokeratoma. Br J Dermatol 10:113-117, 1898
3. th ed), edited by SCRIVER CR, BEAUDET AL, SLY WS, et al, New York, McGraw-Hill; 2001, pp 3733-3774
4. MOORE DF, ALTARESU G, GEOFFREY SF, et al: Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33:525-531, 2002
5. THADHANI R, WOLF M, WEST ML, et al: Patients with Fabry disease on dialysis in the United States. Kidney Int 61:249-255, 2002
6. LINHART A, PALECEK T, BULTAS J, et al: New insights in cardiac structural changes in patients with Fabry disease. Am Heart J 139:1101-1108, 2000
7. FRUSTRACI A, CHIMENT C, RICCI R, et al: Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose infusion therapy. N Engl J Med 345:9-16, 2001
8. CANTOR WJ, BUTANY J, CUSIMAO RJ, IWANOCHKO M: Restrictive cardiomyopathy secondary to Fabry's disease. Circulation 98:1457-1459, 1998
9. VON SCHEIDT W, ENG CM, FITZMAURICE TF, et al: An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 324:395-399, 1991
10. POCHIS WT, LITZOW JT, KING BG, KENNY D: Electrophysiologic findings in Fabry's disease with a short PR interval. Am J Cardiol 74:203-204, 1994
11. ECKART RE, KINNEY KG, BELNAP CM, LE TD: Ventricular fibrillation refractory to automatic internal cardiac defibrillator in Fabry's disease. Cardiology 94:208-212, 2000
12. MITSIAS P, LEVINE SR: Cerebrovascular complications of Fabry's disease. Ann Neurol 40:8-17, 1996
13. MENDEZ MF, STANLEY TM, MEDEL NM, et al: The vascular dementia of Fabry's disease. Dement Geriatr Cogn Disord 8:252-257, 1997
14. HEIMDAL A, STØYLEN A, TORP H, et al: Real-time strain rate imaging of the left ventricle by ultrasound. J Am Soc Echocardiogr 11:1013-1019, 1998
15. URHEIM S, EDVARDSEN T, TORP T, et al: Myocardial strain by Doppler echocardiography. Validation of a new method to quantify regional myocardial function. Circulation 102:1158-1164, 2000
16. WEIDEMANN F, EYSKENS B, MERTENS L, et al: Quantification of regional right and left ventricular function by ultrasonic strain rate and strain indices after surgical repair of tetralogy of fallot. Am J Cardiol 90:133-138, 2002
17. SHIMADA T, SHIMADA K, SAKANE T, et al: Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 110:520-527, 2001
18. WASSMUTH R, LENTZSCH S, ERDBRUEGGER U, et al: Subclinical cardio toxic effects of anthracyclines as assessed by magnetic resonance imaging - a pilot study. Am Heart J 141:1007-1013, 2001
19. NEUBAUER S: High-energy phosphate metabolism in normal, hypertrophied and failing human myocardium. Heart Fail Rev 4:269-280, 1999
20. 31P NMR spectroscopy. Magn Reson Med 39:679-685, 1999
21. SCHIFFMANN R, KOPP JB, AUSTIN HA III, et al: Enzyme replacement therapy in Fabry disease: A randomised controlled trial. JAMA 285:2743-2749, 2001
22. ENG CM, GUFFON N, WILCOX WR, et al: Safety and efficacy of recombinant human α-galactosidase A replacement in Fabry disease. N Engl J Med 345:9-16, 2001
23. JUNG SC, HAS IP, LIMAYE A, et al: Adenó-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of fabry mice. Proc Natl Acad Sci USA 98:2676-2681, 2001
24. ABE A, GREGORY S, KULKARNY A, et al: Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest 105:1563-1571, 2000
25. BISHOP DF, CALHOUN DH, BERNSTEIN, HANZOPOULOS P, QUINN M, DESNICK RJ: Human α-galactosidase A: Nucleotide sequence of a c-DNA clone encoding the mature enzyme. Proc Natl Acad Sci 83:4859-4863, 1986
26. SCHIFFMANN R, MURRAY GJ, TRECO D, et al: Infusion of alfa galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 97:365-370, 2000
27. ENG CM, BANIKAZEMI M, GORDON RE, et al: A phase I/II clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711-722, 2001
28. WHYBRA C, KAMPMANN C, BECK M, et al: Anderson-Fabry disease: Clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24:715-724, 2001
29. MCDERMOT KD, HOLMES A, MINERS AH: Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769-775, 2001
30. SACHDEV B, TAKENAKA T, TERAGUCHI H, et al: Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105:1407-1411, 2002
31. NAKAO S, TAKENAKA T, MAEDA M, et al: An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333:288-293, 1995
32. DESNICK RJ, BANIKAZEMI M, WASSERSTEIN M: Enzyme replacement therapy for Fabry disease, an inherited nephropathy. Clin Nephrol 57:1-8, 2002